Interestingly, treatment of p53-mutant pancreatic cancers with imatinib, an inhibitor of PDGFRβ signaling, is effectively able to impair cell invasion and metastasis [91]. This evidence concerns the gene PDGFRB and familial pancreatic carcinoma.